|
|
|
|
|
(State or other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
| Item 2.02. |
Results of Operations and Financial Condition.
|
| Item 7.01. |
Regulation FD Disclosure.
|
| Item 9.01. |
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits
|
|
|
Press Release dated April 27, 2022
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
TURNING POINT BRANDS, INC.
|
|||
|
Dated: April 27, 2022
|
By:
|
/s/ Brittani N. Cushman
|
|
|
Brittani N. Cushman
|
|||
|
Senior Vice President, General Counsel and Secretary
|
|||
|
|
| • |
Net sales decreased 6.3 percent to $100.9 million
|
| o |
Net sales for Zig-Zag and Stoker’s Products increased 10.1 percent
|
| • |
Gross profit decreased 2.8 percent to $51.8 million
|
| • |
Net income decreased 6.7 percent to $11.0 million
|
| • |
Adjusted EBITDA decreased 9.8 percent to $25.3 million (see Schedule A for a reconciliation to net income)
|
| • |
Diluted EPS of $0.55 and Adjusted Diluted EPS of $0.71 as compared to $0.57 and $0.80 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)
|
| • |
$1.3 million of restructuring expenses compared to none in the previous year
|
| • |
$0.3 million of ERP / CRM scoping expenses compared to none in the previous year
|
| • |
$1.1 million of stock options, restricted stock and incentive expense compared to $1.5 million in the year-ago period
|
| • |
$0.4 million of transaction expenses compared to $0.6 million in the year-ago period
|
| • |
$1.1 million of FDA PMTA-related expenses compared to $0.3 million in the year-ago period
|
| • |
| • |
$1.5 million from the accounting consolidation of Turning Point Brands Canada compared to $0.8 in the year-ago period with the increase driven by the inclusion of the DVW acquisition in the
current period
|
|
Three Months Ended March 31,
|
||||||||
|
2022
|
2021
|
|||||||
|
Net sales
|
$
|
100,894
|
$
|
107,641
|
||||
|
Cost of sales
|
49,100
|
54,380
|
||||||
|
Gross profit
|
51,794
|
53,261
|
||||||
|
Selling, general, and administrative expenses
|
32,565
|
28,912
|
||||||
|
Operating income
|
19,229
|
24,349
|
||||||
|
Interest expense, net
|
5,196
|
4,486
|
||||||
|
Investment income
|
(78
|
)
|
(25
|
)
|
||||
|
Loss on extinguishment of debt
|
-
|
5,706
|
||||||
|
Income before income taxes
|
14,111
|
14,182
|
||||||
|
Income tax expense
|
3,340
|
2,654
|
||||||
|
Consolidated net income
|
10,771
|
11,528
|
||||||
|
Net loss attributable to non-controlling interest
|
(227
|
)
|
(255
|
)
|
||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
10,998
|
$
|
11,783
|
||||
|
Basic income per common share:
|
||||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.60
|
$
|
0.62
|
||||
|
Diluted income per common share:
|
||||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.55
|
$
|
0.57
|
||||
|
Weighted average common shares outstanding:
|
||||||||
|
Basic
|
18,257,695
|
19,093,961
|
||||||
|
Diluted
|
21,749,510
|
22,665,067
|
||||||
|
Supplemental disclosures of statements of income information:
|
||||||||
|
Excise tax expense
|
$
|
5,709
|
$
|
8,789
|
||||
|
FDA fees
|
$
|
124
|
$
|
170
|
||||
|
ASSETS
|
March 31,
2022
|
December 31,
2021
|
||||||
|
Current assets:
|
||||||||
|
Cash
|
$
|
126,045
|
$
|
128,320
|
||||
|
Accounts receivable, net of allowances of $177 in 2022 and $262 in 2021
|
9,450
|
6,496
|
||||||
|
Inventories
|
105,858
|
87,607
|
||||||
|
Other current assets
|
25,663
|
26,746
|
||||||
|
Total current assets
|
267,016
|
249,169
|
||||||
|
Property, plant, and equipment, net
|
20,567
|
18,650
|
||||||
|
Deferred income taxes
|
1,754
|
1,363
|
||||||
|
Right of use assets
|
14,405
|
15,053
|
||||||
|
Deferred financing costs, net
|
362
|
388
|
||||||
|
Goodwill
|
162,323
|
162,333
|
||||||
|
Other intangible assets, net
|
87,022
|
87,485
|
||||||
|
Master Settlement Agreement (MSA) escrow deposits
|
30,237
|
31,720
|
||||||
|
Other assets
|
35,017
|
35,399
|
||||||
|
Total assets
|
$
|
618,703
|
$
|
601,560
|
||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
29,464
|
$
|
7,361
|
||||
|
Accrued liabilities
|
29,921
|
32,937
|
||||||
|
Other current liabilities
|
38
|
38
|
||||||
|
Total current liabilities
|
59,423
|
40,336
|
||||||
|
Notes payable and long-term debt
|
414,791
|
414,172
|
||||||
|
Lease liabilities
|
12,625
|
13,336
|
||||||
|
Total liabilities
|
486,839
|
467,844
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders' equity:
|
||||||||
|
Preferred stock; $0.01 par value; authorized shares 40,000,000; issued and outstanding
shares -0-
|
-
|
-
|
||||||
|
Common stock,
voting, $0.01 par value; authorized shares, 190,000,000; 19,785,806 issued shares and 18,180,174 outstanding shares at March 31, 2022, and 19,690,884 issued shares and 18,395,476 outstanding shares at December 31, 2021
|
198
|
197
|
||||||
|
Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000;issued and
outstanding shares -0-
|
-
|
-
|
||||||
|
Additional paid-in capital
|
109,073
|
108,811
|
||||||
|
Cost of repurchased common stock (1,605,632 shares at March 31, 2022 and 1,295,408 shares at December 31, 2021)
|
(59,491
|
)
|
(48,869
|
)
|
||||
|
Accumulated other comprehensive loss
|
(1,326
|
)
|
(195
|
)
|
||||
|
Accumulated earnings
|
81,327
|
71,460
|
||||||
|
Non-controlling interest
|
2,083
|
2,312
|
||||||
|
Total stockholders' equity
|
131,864
|
133,716
|
||||||
|
Total liabilities and stockholders' equity
|
$
|
618,703
|
$
|
601,560
|
||||
|
Three Months Ended March 31,
|
||||||||
|
2022
|
2021
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Consolidated net income
|
$
|
10,771
|
$
|
11,528
|
||||
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
|
Loss on extinguishment of debt
|
-
|
5,706
|
||||||
|
Loss (gain) on sale of property, plant, and equipment
|
1
|
(2
|
)
|
|||||
|
Depreciation expense
|
871
|
788
|
||||||
|
Amortization of other intangible assets
|
463
|
477
|
||||||
|
Amortization of deferred financing costs
|
645
|
604
|
||||||
|
Deferred income tax (benefit) expense
|
(34
|
)
|
552
|
|||||
|
Stock compensation expense
|
1,159
|
1,498
|
||||||
|
Noncash lease (income) expense
|
(5
|
)
|
6
|
|||||
|
Gain on investments
|
(14
|
)
|
(13
|
)
|
||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
(2,958
|
)
|
2,735
|
|||||
|
Inventories
|
(18,258
|
)
|
(12,461
|
)
|
||||
|
Other current assets
|
1,081
|
1,283
|
||||||
|
Other assets
|
382
|
464
|
||||||
|
Accounts payable
|
22,101
|
14,882
|
||||||
|
Accrued liabilities and other
|
(3,165
|
)
|
(3,806
|
)
|
||||
|
Net cash provided by operating activities
|
$
|
13,040
|
$
|
24,241
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Capital expenditures
|
$
|
(2,787
|
)
|
$
|
(842
|
)
|
||
|
Restricted cash, MSA escrow deposits
|
(8,468
|
)
|
(14,920
|
)
|
||||
|
Proceeds on the sale of property, plant and equipment
|
1
|
2
|
||||||
|
Net cash used in investing activities
|
$
|
(11,254
|
)
|
$
|
(15,760
|
)
|
||
|
Cash flows from financing activities:
|
||||||||
|
Proceeds from Senior Secured Notes
|
$
|
-
|
$
|
250,000
|
||||
|
Payments of 2018 first lien term loan
|
-
|
(130,000
|
)
|
|||||
|
Settlement of interest rate swaps
|
-
|
(3,573
|
)
|
|||||
|
Payment of dividends
|
(1,022
|
)
|
(958
|
)
|
||||
|
Payments of financing costs
|
-
|
(6,614
|
)
|
|||||
|
Exercise of options
|
245
|
425
|
||||||
|
Redemption of options
|
-
|
(1,466
|
)
|
|||||
|
Redemption of performance restricted stock units
|
(1,141
|
)
|
-
|
|||||
|
Common stock repurchased
|
(10,622
|
)
|
(5,733
|
)
|
||||
|
Net cash provided by (used in) financing activities
|
$
|
(12,540
|
)
|
$
|
102,081
|
|||
|
Net (decrease) increase in cash
|
$
|
(10,754
|
)
|
$
|
110,562
|
|||
|
Effect of foreign currency translation on cash
|
$
|
(3
|
)
|
$
|
101
|
|||
|
Cash, beginning of period:
|
||||||||
|
Unrestricted
|
128,320
|
41,765
|
||||||
|
Restricted
|
15,155
|
35,074
|
||||||
|
Total cash at beginning of period
|
143,475
|
76,839
|
||||||
|
Cash, end of period:
|
||||||||
|
Unrestricted
|
126,045
|
167,361
|
||||||
|
Restricted
|
6,673
|
20,141
|
||||||
|
Total cash at end of period
|
$
|
132,718
|
$
|
187,502
|
||||
|
Three Months Ended
March 31,
|
||||||||
|
2022
|
2021
|
|||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
10,998
|
$
|
11,783
|
||||
|
Add:
|
||||||||
|
Interest expense, net
|
5,196
|
4,486
|
||||||
|
Loss on extinguishment of debt
|
-
|
5,706
|
||||||
|
Income tax expense
|
3,340
|
2,654
|
||||||
|
Depreciation expense
|
871
|
788
|
||||||
|
Amortization expense
|
463
|
477
|
||||||
|
EBITDA
|
$
|
20,868
|
$
|
25,894
|
||||
|
Components of Adjusted EBITDA
|
||||||||
|
Corporate restructuring (a)
|
1,332
|
-
|
||||||
|
ERP/CRM (b)
|
330
|
-
|
||||||
|
Stock options, restricted stock, and incentives expense (c)
|
1,159
|
1,498
|
||||||
|
Transactional expenses (d)
|
425
|
607
|
||||||
|
FDA PMTA (e)
|
1,139
|
-
|
||||||
|
Adjusted EBITDA
|
$
|
25,253
|
$
|
27,999
|
||||
| (a) |
Represents costs associated with corporate restructuring, including severance.
|
| (b) |
Represents cost assosicated with scoping new ERP and CRM systems.
|
| (c) |
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units.
|
| (d) |
Represents the fees incurred for transaction expenses.
|
| (e) |
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").
|
|
Three Months Ended
March 31,
|
||||||||
|
2022
|
2021
|
|||||||
|
GAAP EPS
|
$
|
0.55
|
$
|
0.57
|
||||
|
Corporate restructuring (a)
|
0.05
|
-
|
||||||
|
ERP/CRM (b)
|
0.01
|
0.05
|
||||||
|
Loss on extinguishment of debt (c)
|
-
|
0.20
|
||||||
|
Stock options, restricted stock, and incentives expense (d)
|
0.04
|
0.05
|
||||||
|
Transactional expenses (e)
|
0.01
|
0.02
|
||||||
|
FDA PMTA (f)
|
0.04
|
-
|
||||||
|
Tax (expense) benefit (g)
|
0.01
|
(0.10
|
)
|
|||||
|
Adjusted diluted EPS
|
$
|
0.71
|
$
|
0.80
|
||||
|
Totals may not foot due to rounding
|
| (a) |
Represents costs associated with corporate restructuring, including severance, tax effected at the quarterly tax rate.
|
| (b) |
Represents cost assosicated with scoping new ERP and CRM systems tax effected at the quarterly tax rate.
|
| (c) |
Represents Loss on Extinguishment of Debt tax effected at the quarterly tax rate.
|
| (d) |
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate.
|
| (e) |
Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate.
|
| (f) |
Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate.
|
| (g) |
Represents adjustment from quarterly tax rate to annual projected tax rate of 23% in 2022 and 2021.
|
|
Consolidated
|
Zig-Zag Products
|
Stoker's Products
|
NewGen Products
|
|||||||||||||||||||||||||||||
|
1st Quarter
2022
|
1st Quarter
2021
|
1st Quarter
2022
|
1st Quarter
2021
|
1st Quarter
2022
|
1st Quarter
2021
|
1st Quarter
2022
|
1st Quarter
2021 |
|||||||||||||||||||||||||
|
Net sales
|
$
|
100,894
|
$
|
107,641
|
$
|
45,672
|
$
|
41,004
|
$
|
31,703
|
$
|
29,255
|
$
|
23,519
|
$
|
37,382
|
||||||||||||||||
|
Gross profit
|
$
|
51,794
|
$
|
53,261
|
$
|
26,343
|
$
|
24,896
|
$
|
17,686
|
$
|
15,892
|
$
|
7,765
|
$
|
12,473
|
||||||||||||||||
|
Operating income
|
$
|
19,229
|
$
|
24,349
|
$
|
18,737
|
$
|
19,437
|
$
|
13,506
|
$
|
12,255
|
$
|
678
|
$
|
2,006
|
||||||||||||||||
|
Adjustments:
|
||||||||||||||||||||||||||||||||
|
Corporate restructuring
|
1,332
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
ERP/CRM
|
330
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||||||||||
|
Transactional expenses
|
425
|
607
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
FDA PMTA
|
1,139
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
Adjusted operating income
|
$
|
22,455
|
$
|
24,956
|
$
|
18,737
|
$
|
19,437
|
$
|
13,506
|
$
|
12,255
|
$
|
678
|
$
|
2,006
|
||||||||||||||||